Aminocaproic acid 5% bottle 100ml

Composition

Solution for infusion 5%
1 ml contains aminocaproic acid 50 mg
100 or 200 ml in a bottle.

Mechanism of action

Aminocaproic acid is a hemostatic agent, an inhibitor of fibrinolysis. It blocks the action of plasminogen activators, inhibits the action of plasmin, partially inhibits kinins. Aminocaproic acid also has some antiallergic activity and slightly increases the antitoxic function of the liver.

To stop bleeding during surgical interventions and various pathological conditions, accompanied by increased fibrinolytic activity of the blood and tissues (after operations on the lungs, prostate, pancreas and thyroid gland). Prevention of the development of secondary hyperfibrinogenemia with massive transfusions of canned blood.

Dosage and administration

Aminocaproic acid solution is administered intravenously.

For adults, the drug is administered intravenously in the form of a 5% solution in an amount up to 100 ml drip at a rate of 50–60 drops per minute (for 15–30 minutes). During the first hour it is recommended to inject 4–5 g (80–100 ml) of the preparation, and then, if necessary, 1 g (20 ml) every hour for about 8 hours or until the bleeding stops. In the case of continuing or re-bleeding injection of a 5% solution of aminocaproic acid, repeat every 4 hours.

The introduction of aminocaproic acid solution can be combined with the infusion of glucose solution, hydrolysates and antishock solutions. In acute fibrinolysis, when the content of fibrinogen in the blood drops sharply, the administration of aminocaproic acid must be supplemented with a subsequent infusion of fibrinogen.

Contraindications

Hypersensitivity, hypercoagulation (thrombosis, thromboembolism), the tendency to thrombosis and thromboembolic diseases, disorders of cerebral circulation, DIC, pregnancy.With caution. Arterial hypotension, valvular heart disease, insufficiency, CRF.

Dizziness, tinnitus, headache, nausea, diarrhea, nasal congestion, skin rash, lowering blood pressure, orthostatic hypotension, convulsions, rhabdomyolysis, myoglobinuria, acute renal failure, subendocardial hemorrhage.

Cautions

In the appointment of aminocaproic acid, it is necessary to control the fibrinolytic activity of the blood and the content of fibrinogen.
There are reports of inappropriate use in women for the prevention of elevated blood loss during childbirth due to the possibility of thromboembolic complications in the postpartum period.

Storage conditions

In a dry, dark place and out of reach of children, at a temperature not higher than 25 ° C.

- 2 years.